Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
9.03
-0.01 (-0.11%)
At close: Dec 20, 2024, 4:00 PM
8.99
-0.04 (-0.44%)
After-hours: Dec 20, 2024, 4:06 PM EST
Company Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States.
It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Aurinia Pharmaceuticals Inc.
| Country | Canada |
| Founded | 1993 |
| IPO Date | Jan 26, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 300 |
| CEO | Peter Greenleaf |
Contact Details
Address: 118 Avenue , 14315, Suite 140 Edmonton, AB T5L 4S6 Canada | |
| Phone | 250 744 2487 |
| Website | auriniapharma.com |
Stock Details
| Ticker Symbol | AUPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001600620 |
| CUSIP Number | 05156V102 |
| ISIN Number | CA05156V1022 |
| Employer ID | 98-1231763 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter S. Greenleaf M.B.A. | Chief Executive Officer and Director |
| Joseph M. Miller CPA | Chief Financial Officer |
| Matthew Maxwell Donley M.B.A. | Chief Operations Officer |
| Stephen P. Robertson | Executive Vice President of General Counsel |
| Andrea Levin Christopher | Head of the Corporate Communications and Investor Relations |
| Michael R. Martin | Chief Business Officer |
| Sue Evans | Senior Vice President of Global Regulatory Affairs |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing and Supply Chain |
| DeDe Sheel | Vice President of Investor Relation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 12, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 12, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 4, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |